Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
capecitabine RTD · 1 trial · 1 indication
| Arm | Type | Description |
|---|---|---|
| Capecitabine RTD | EXPERIMENTAL | - |
| Xeloda | ACTIVE_COMPARATOR | - |
| Name | Type | Description |
|---|---|---|
| capecitabine RTD | DRUG | single oral dose |
| capecitabine [Xeloda] | DRUG | single oral dose |
Inclusion Criteria: * Adult patients,\>/= 18 years of age * Histological/cytological confirmation of colorectal or breast cancer * Patient is ambulatory and has a Karnofsky performance status of \> 70% * Body surface area between 1.5 and 2.0 m2 * Either: * Due to receive Xeloda as monotherapy or as...
Capecitabine RTD is a rapid disintegrating tablet formulation of capecitabine developed by Roche Holding AG. It is an investigational small molecule being studied in breast cancer and colorectal cancer. The rapid disintegrating tablet is designed as an alternative oral form of capecitabine, which is also marketed as Xeloda.
Capecitabine RTD is being studied for the treatment of breast cancer and colorectal cancer. It is an oral small molecule formulation of capecitabine, and its development focuses on these two solid tumor types. It remains investigational and is not established as an approved treatment in this rapid disintegrating tablet form.
Capecitabine RTD targets thymidylate synthase, also known as TYMS. It acts as an inhibitor of this enzyme. Thymidylate synthase is involved in DNA synthesis, and inhibiting it interferes with the ability of cancer cells to replicate, which is the basis for its use in breast and colorectal cancer research.
Capecitabine RTD is developed by Roche Holding AG, which trades under the ticker RHHBY. Roche is the company behind the rapid disintegrating tablet formulation of capecitabine studied in solid tumors. The same company markets the commercial capecitabine product Xeloda.
Capecitabine RTD is in Phase 1 clinical development. It is an investigational formulation and has not been established as an approved product in this rapid disintegrating tablet form. The Phase 1 program has been completed, with no active trials currently listed for this formulation.
Capecitabine RTD was studied in one completed Phase 1 trial, NCT01493336, titled a study of capecitabine rapid disintegrating tablets versus commercial Xeloda in patients with solid tumours. That trial enrolled 37 participants across Australia, New Zealand, and the United Kingdom, and it was randomized and active controlled.